The short version of GHS-R1a fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-20 and is reviewed periodically as new material appears.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with amidated C-terminus |
| Molecular weight | 711.85 g/mol | Monoisotopic mass |
| Primary receptor | GHS-R1a | Ghrelin receptor, Gq/11 coupled |
| Peptide class | Synthetic pentapeptide | Contains two non-natural residues |
| Reported selectivity | Lower cortisol and prolactin effect | Observed in animal and early human work |
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
In August 2020, British and American officials stated that the Gam-COVID-Vac vaccine would likely be rejected due to concerns that the normally rigorous process of vaccine clinical testing was not followed. As of December 2020, Belarus and Argentina granted emergency use authorization for the vector-based vaccine. On 21 January 2021, Hungary became the first European Union country to register the shot for emergency use, as well as the United Arab Emirates in the Persian Gulf region. On 19 January 2021, the Russian authorities applied for the registration of Sputnik V in the European Union, according to the RDIF. On 10 February, the European Medicines Agency (EMA) said that they had "not received an application for a rolling review or a marketing authorisation for the vaccine". The developers have only expressed their interest that the vaccine be considered for a rolling review, but EMA's Human Medicines Committee (CHMP) and the COVID-19 EMA pandemic Task Force (COVID-ETF) need to give their agreement first before developers can submit their application for initiation of the rolling review process. On 4 March 2021, the Committee for Medicinal Products for Human Use (CHMP) of the EMA started a rolling review of Sputnik V. The EU applicant is R-Pharm Germany GmbH, a subsidiary of the Russian R-Pharm. On 16 June, Reuters reported that approval of Sputnik V will be delayed at least until September because not all the necessary clinical data has been submitted by the deadline.
Another case was that of Ismil bin Kadar, who was initially sentenced to death for a 2005 robbery-murder case in Boon Lay, but eventually acquitted of the crime as the Court of Appeal found that based on the evidence, Ismil was not involved in the case and that it was solely his younger brother Muhammad bin Kadar who was responsible for the robbery and murder; Muhammad was subsequently executed in April 2015. Successful clemency applications are thought to be even rarer. Since 1965, the presidential clemency has been granted seven times to death row inmates, whose sentences were all commuted to life imprisonment (not counting the clemency pleas of the underaged offenders serving TPP). The most recent case was in August 2025, when convicted drug trafficker Tristan Tan Yi Rui was granted clemency by President Tharman Shanmugaratnam, who commuted Tan's death sentence to life imprisonment. Prior to Tan's pardon, the last presidential clemency to be granted was in April 1998, when President Ong Teng Cheong pardoned a 19-year-old death row inmate and convicted murderer Mathavakannan Kalimuthu, commuting his death sentence to life imprisonment. Previously, other than the Court of Appeal, offenders were allowed to file criminal or civil appeals to the Privy Council in London, where the judges could hear their appeals once they exhausted all avenues of appeal in Singapore. This avenue of appeal was fully abolished for all criminal and civil matters in April 1994. One case in which an appeal to the Privy Council was successful was the case of murderer Mohamed Yasin bin Hussin.
===== GPIIb/IIIa activation ===== Collagen-mediated GPVI signalling increases the platelet production of thromboxane A2 (TXA2) and decreases the production of prostacyclin. This occurs by altering the metabolic flux of platelet's eicosanoid synthesis pathway, which involves enzymes phospholipase A2, cyclo-oxygenase 1, and thromboxane-A synthase. Platelets secrete thromboxane A2, which acts on the platelet's own thromboxane receptors on the platelet surface (hence the so-called "out-in" mechanism), and those of other platelets. These receptors trigger intraplatelet signaling, which converts GPIIb/IIIa receptors to their active form to initiate aggregation.
Sources: en.wikipedia.org
== Explanation == The surface plasmon polariton is a non-radiative electromagnetic surface wave that propagates in a direction parallel to the negative permittivity/dielectric material interface. Since the wave is on the boundary of the conductor and the external medium (air, water or vacuum for example), these oscillations are very sensitive to any change of this boundary, such as the adsorption of molecules to the conducting surface. To describe the existence and properties of surface plasmon polaritons, one can choose from various models (quantum theory, Drude model, etc.). The simplest way to approach the problem is to treat each material as a homogeneous continuum, described by a frequency-dependent relative permittivity between the external medium and the surface. This quantity, hereafter referred to as the materials' "dielectric function", is the complex permittivity. In order for the terms that describe the electronic surface plasmon to exist, the real part of the dielectric constant of the conductor must be negative and its magnitude must be greater than that of the dielectric. This condition is met in the infrared-visible wavelength region for air/metal and water/metal interfaces (where the real dielectric constant of a metal is negative and that of air or water is positive). LSPRs (localized surface plasmon resonances) are collective electron charge oscillations in metallic nanoparticles that are excited by light. They exhibit enhanced near-field amplitude at the resonance wavelength.
Unable to afford the TCB Band, the group featured guitarists Jock Bartley and Larry Coryell, Neil Flanz on pedal steel, bassist Kyle Tullis, and drummer N. D. Smart. The touring party also included Parsons' new wife, Gretchen Parsons, who was envious of Harris and her young daughter. Coordinating the spectacle as road manager was Phil Kaufman, who had served time with Charles Manson on Terminal Island but who ensured that the performer stayed clear of drugs and limited his alcohol intake during shows. At first, the band was under-rehearsed and played poorly; however, they improved with steady gigging and received rapturous responses at several counter-cultural venues, including Armadillo World Headquarters in Austin, Max's Kansas City in New York City, and Liberty Hall in Houston, where Neil Young and Linda Ronstadt sat in for a filmed performance. Nevertheless, the tour failed to galvanize sales of GP, which never charted in the Billboard 200. For his next and final album, 1974's posthumously released Grievous Angel, Parsons used Harris and members of the TCB Band. The record received more enthusiastic reviews than GP. Although Parsons only contributed two new songs to the album ("In My Hour of Darkness" and "Return of the Grievous Angel"), he was reportedly enthusiastic with his new sound and seemed to have finally adopted a diligent mindset to his musical career, limiting his intake of alcohol and opiates during most of the sessions. Grievous Angel peaked at number 195 on the Billboard chart.
The main symptoms of RA are joint pain, swelling, and stiffness, which are usually worst in the morning or after resting. Joint affected by RA are often tender when pressed or moved. Morning stiffness can last for several hours but gradually improves with movement and physical activity.This is different from osteoarthritis, where stiffness doesn't last as long. The symptoms of RA can make it difficult to perform everyday tasks, interfere with sleep, and reduce overall quality of life. RA usually develops gradually and often begins by affecting the small joints of the hands (metacarpophalangeal and proximal interphalangeal joints) and feet before spreading to larger joints. The condition can affect any joint, tendon, or bursa that contains synovial tissue, including the elbows, shoulders, ankles, knees, hips, and jaw. RA is polyarticular, meaning it affects multiple joints. Although RA usually affects the same joints on both sides of the body, this symmetry may not be present in the early stages. RA can be difficult to detect when it first develops because inflammation of the synovial membrane (synovitis) may not be visible early on. Signs of synovitis include soft, spongy swelling around a joint. Joint deformities are not seen early in the disease but can develop over time if RA is severe, chronic, or left untreated, and can potentially lead to significant disability. As the pathology progresses, the inflammatory activity leads to tendon tethering and erosion and destruction of the joint surface, which impairs range of movement and leads to deformity.
Sources: en.wikipedia.org
== Further reading == Bishop, Michael; Duben-Engelkirk, Janet L., and Fody, Edward P. (1992). "Chapter 19, Liver Function, Clinical Chemistry Principles, Procedures, Correlations, 2nd Ed." Philadelphia, J.B. Lippincott Company. Miyabara, Yuichi; Tabata, Masako; Suzuki, Junzo; Suzuki, Shizuo (1992). "Separation and sensitive determination of i-urobilin and 1-stercobilin by high-performance liquid chromatography with fluorimetric detection". Journal of Chromatography B: Biomedical Sciences and Applications. 574 (2): 261–265. doi:10.1016/0378-4347(92)80038-R. PMID 1618958. Miyabara, Y.; Sakata, Y.; Suzuki, J.; Suzuki, S. (1994). "Estimation of faecal pollution based on the amounts of urobilins in urban rivers". Environmental Pollution. 84 (2): 117–122. doi:10.1016/0269-7491(94)90093-0. PMID 15091706. Munson-Ringsrud, Karen and Jorgenson-Linné, Jean (1995). "Urinalysis and Body Fluids, a ColorText and Atlas." St. Louis, Mosby. Nelson, L.; David, Cox M.M. (2005). “Chapter 22 – Biosynthesis of Amino Acids, Nucleotides, and Related Molecules”, pp. 856, In Lehninger Principles of Biochemistry. Freeman, New York. pp. 856. Voet, Donald; Voet, Judith G.; Pratt, Charlotte W. (2018-01-23). Voet's Principles of Biochemistry, Global Edition, 5th Edition. Wiley. p. 1200. ISBN 978-1-119-45166-2. Retrieved 2024-02-01.
=== Pulmonary function test === The forced vital capacity may be monitored at intervals to detect increasing muscular weakness. Acutely, negative inspiratory force may be used to determine adequacy of ventilation; it is performed on those individuals with MG.
==== 1000–1099 ==== Export of Goods (Control) (Amendment) Order 1993 (S.I. 1993/1020) Foreign Satellite Service Proscription Order 1993 (S.I. 1993/1024) Social Security (Consequential Provisions) Act 1992 Appointed Day Order 1993 (S.I. 1993/1025) Cranfield Airport (Designation) (Detention and Sale of Aircraft) Order 1993 (S.I. 1993/1026) Weymouth and Portland Harbour Revision Order 1993 (S.I. 1993/1027) Town and Country Planning (General Permitted Development) (Scotland) Amendment Order 1993 (S.I. 1993/1036) Gaming Act (Variation of Monetary Limits) (Scotland) Order 1993 (S.I. 1993/1037) Town and Country Planning (Use Classes) (Scotland) Amendment Order 1993 (S.I. 1993/1038) Town and Country Planning (General S.I. 1993/1039) Gaming Clubs (Hours and Charges) (Scotland) Amendment Regulations 1993 (S.I. 1993/1040) Reconstitution of the Bedfordshire and River Ivel Internal Drainage Board Order 1993 (S.I. 1993/1041) Glan Conwy-Conwy Morfa Trunk Road (A547) (Previously known as and forming part of The Chester—Bangor Trunk Road (A55)) Detrunking Order 1993 (S.I. 1993/1057) International Finance Corporation (1991 General Capital Increase) Order 1993 (S.I. 1993/1059) Asian Development Bank (Fifth Replenishment of the Asian Development Fund and Second Regularized Replenishment of the Technical Assistance Special Fund) Order 1993 (S.I. 1993/1060) Banking Appeal Tribunal (Scottish Appeals) Amendment Regulations 1993 (S.I. 1993/1061) Financial Assistance for Environmental Purposes Order 1993 (S.I. 1993/1062) A43 Trunk Road (Silverstone Bypass and Slip Roads) Order 1993 (S.I.
=== Methods of assessment === An increase in prothrombin time, a coagulation assay, has been used as an indicator of vitamin K status, but it lacks sufficient sensitivity and specificity for this application. Serum phylloquinone is the most commonly used marker of vitamin K status. Concentrations <0.15 μg/L are indicative of deficiency. Disadvantages include exclusion of the other vitamin K vitamers and interference from recent dietary intake. Vitamin K is required for the gamma-carboxylation of specific glutamic acid residues within the Gla domain of the 17 vitamin K–dependent proteins. Thus, a rise in uncarboxylated versions of these proteins is an indirect but sensitive and specific marker for vitamin K deficiency.
Sources: en.wikipedia.org
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.
Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.
Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.